These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20868323)

  • 1. Can regenerative medicine save Big Pharma’s business model from the patent cliff?
    Denoon A; Vollebregt E
    Regen Med; 2010 Sep; 5(5):687-90. PubMed ID: 20868323
    [No Abstract]   [Full Text] [Related]  

  • 2. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine.
    Pangarkar N; Pharoah M; Nigam A; Hutmacher DW; Champ S
    Regen Med; 2010 Sep; 5(5):823-35. PubMed ID: 20868336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protecting methods for treatment related to regenerative medicine and gene therapy in Japan.
    Kaneshiro K; Masuda S; Tanaka Y; Tamai K
    Nat Biotechnol; 2004 Mar; 22(3):343-5. PubMed ID: 14990960
    [No Abstract]   [Full Text] [Related]  

  • 4. Japan's patent issues relating to life science therapeutic inventions.
    Tessensohn JA
    Expert Opin Ther Pat; 2014 Sep; 24(9):953-7. PubMed ID: 25089628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patent production is a prerequisite for successful exit of a biopharmaceutical company.
    Saotome C; Nakaya Y; Abe S
    Drug Discov Today; 2016 Mar; 21(3):406-9. PubMed ID: 26721189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human induced pluripotent stem cells: a review of the US patent landscape.
    Georgieva BP; Love JM
    Regen Med; 2010 Jul; 5(4):581-91. PubMed ID: 20632861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intellectual Property in the Field of Regenerative Medicine in Japan.
    Asano S; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1823-1827. PubMed ID: 30458929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regenerative medicine: learning from past examples.
    Couto DS; Perez-Breva L; Cooney CL
    Tissue Eng Part A; 2012 Nov; 18(21-22):2386-93. PubMed ID: 22697402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regenerative medicine research at Pfizer. Interview with Ruth McKernan.
    McKernan R
    Regen Med; 2011 Nov; 6(6 Suppl):62-4. PubMed ID: 21999263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brüstle v. Greenpeace: implications for stem cell research.
    Denoon A
    Regen Med; 2011 Nov; 6(6 Suppl):85-7. PubMed ID: 21999267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Error of judgment.
    Nature; 2011 Dec; 480(7377):291-2. PubMed ID: 22170640
    [No Abstract]   [Full Text] [Related]  

  • 14. Regenerative nanomedicine: ethical, legal, and social issues.
    Glenn LM; Boyce JS
    Methods Mol Biol; 2012; 811():303-16. PubMed ID: 22042687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conference scene: Challenges to commercialization.
    Ilic D; Gentleman E
    Regen Med; 2010 May; 5(3):341-3. PubMed ID: 20455647
    [No Abstract]   [Full Text] [Related]  

  • 16. The CEO of Novartis on growing after a patent cliff.
    Jimenez J
    Harv Bus Rev; 2012 Dec; 90(12):39-42, 135. PubMed ID: 23227577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Very small embryonic-like stem cells for regenerative medicine: WO2010039241.
    Taupin P
    Expert Opin Ther Pat; 2010 Aug; 20(8):1103-6. PubMed ID: 20518618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study: Business Booms for Unlicensed and Unproven Stem Cell Treatments.
    Rubin R
    JAMA; 2022 Feb; 327(5):414-415. PubMed ID: 35019946
    [No Abstract]   [Full Text] [Related]  

  • 19. [Analysis of the market for medical instruments based on patent statistics].
    Aleksandrov EG
    Med Tekh; 2002; (1):28-31. PubMed ID: 11898659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Questions and answers regarding recent Department of Commerce actions involving recombinant DNA patent applications.
    Eden D
    Basic Life Sci; 1977; 9():507-13. PubMed ID: 921700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.